DNA
Price
$10.82
Change
-$0.61 (-5.34%)
Updated
Feb 21 closing price
Capitalization
621.92M
NTLA
Price
$12.17
Change
-$0.08 (-0.65%)
Updated
Feb 21 closing price
Capitalization
1.24B
4 days until earnings call
Ad is loading...

DNA vs NTLA

Header iconDNA vs NTLA Comparison
Open Charts DNA vs NTLABanner chart's image
Ginkgo Bioworks Holdings
Price$10.82
Change-$0.61 (-5.34%)
Volume$2.03M
Capitalization621.92M
Intellia Therapeutics
Price$12.17
Change-$0.08 (-0.65%)
Volume$4.45M
Capitalization1.24B
DNA vs NTLA Comparison Chart
Loading...
DNA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
NTLA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
DNA vs. NTLA commentary
Feb 23, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is DNA is a Hold and NTLA is a Hold.

Ad is loading...
COMPARISON
Comparison
Feb 23, 2025
Stock price -- (DNA: $10.82 vs. NTLA: $12.17)
Brand notoriety: DNA and NTLA are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: DNA: 123% vs. NTLA: 144%
Market capitalization -- DNA: $621.92M vs. NTLA: $1.24B
DNA [@Biotechnology] is valued at $621.92M. NTLA’s [@Biotechnology] market capitalization is $1.24B. The market cap for tickers in the [@Biotechnology] industry ranges from $393.7B to $0. The average market capitalization across the [@Biotechnology] industry is $2.51B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

DNA’s FA Score shows that 1 FA rating(s) are green whileNTLA’s FA Score has 1 green FA rating(s).

  • DNA’s FA Score: 1 green, 4 red.
  • NTLA’s FA Score: 1 green, 4 red.
According to our system of comparison, both DNA and NTLA are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

DNA’s TA Score shows that 3 TA indicator(s) are bullish while NTLA’s TA Score has 5 bullish TA indicator(s).

  • DNA’s TA Score: 3 bullish, 6 bearish.
  • NTLA’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, NTLA is a better buy in the short-term than DNA.

Price Growth

DNA (@Biotechnology) experienced а -26.54% price change this week, while NTLA (@Biotechnology) price change was +13.74% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -1.71%. For the same industry, the average monthly price growth was -2.01%, and the average quarterly price growth was +0.86%.

Reported Earning Dates

DNA is expected to report earnings on Nov 11, 2024.

NTLA is expected to report earnings on May 01, 2025.

Industries' Descriptions

@Biotechnology (-1.71% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
NTLA($1.24B) has a higher market cap than DNA($622M). DNA YTD gains are higher at: 10.183 vs. NTLA (4.374). NTLA has higher annual earnings (EBITDA): -527.52M vs. DNA (-630.64M). NTLA has more cash in the bank: 658M vs. DNA (616M). NTLA has less debt than DNA: NTLA (102M) vs DNA (446M). DNA has higher revenues than NTLA: DNA (217M) vs NTLA (43.1M).
DNANTLADNA / NTLA
Capitalization622M1.24B50%
EBITDA-630.64M-527.52M120%
Gain YTD10.1834.374233%
P/E RatioN/AN/A-
Revenue217M43.1M503%
Total Cash616M658M94%
Total Debt446M102M437%
FUNDAMENTALS RATINGS
NTLA: Fundamental Ratings
NTLA
OUTLOOK RATING
1..100
21
VALUATION
overvalued / fair valued / undervalued
1..100
32
Undervalued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
96
PRICE GROWTH RATING
1..100
64
P/E GROWTH RATING
1..100
100
SEASONALITY SCORE
1..100
n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
DNANTLA
RSI
ODDS (%)
Bearish Trend 3 days ago
84%
Bullish Trend 3 days ago
77%
Stochastic
ODDS (%)
Bullish Trend 3 days ago
84%
Bearish Trend 3 days ago
90%
Momentum
ODDS (%)
Bearish Trend 3 days ago
83%
Bullish Trend 3 days ago
80%
MACD
ODDS (%)
Bearish Trend 3 days ago
90%
Bullish Trend 3 days ago
78%
TrendWeek
ODDS (%)
Bearish Trend 3 days ago
84%
Bullish Trend 3 days ago
80%
TrendMonth
ODDS (%)
Bearish Trend 3 days ago
86%
Bullish Trend 3 days ago
81%
Advances
ODDS (%)
Bullish Trend 10 days ago
81%
Bullish Trend 5 days ago
78%
Declines
ODDS (%)
Bearish Trend 3 days ago
85%
Bearish Trend 3 days ago
86%
BollingerBands
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 3 days ago
85%
Aroon
ODDS (%)
Bullish Trend 3 days ago
78%
Bearish Trend 3 days ago
89%
View a ticker or compare two or three
Ad is loading...
DNA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
NTLA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
MVGJX16.93-0.09
-0.53%
MFS Low Volatility Global Equity R1
NBRAX26.19-0.58
-2.17%
Neuberger Berman M/C Intrinsic Val A
LGRNX30.19-0.70
-2.27%
Loomis Sayles Growth N
HBMCX26.82-0.74
-2.69%
Hartford MidCap HLS IB
PEGCX19.42-0.76
-3.77%
PGIM Jennison Mid-Cap Growth C

DNA and

Correlation & Price change

A.I.dvisor indicates that over the last year, DNA has been loosely correlated with VCYT. These tickers have moved in lockstep 58% of the time. This A.I.-generated data suggests there is some statistical probability that if DNA jumps, then VCYT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To DNA
1D Price
Change %
DNA100%
-5.34%
VCYT - DNA
58%
Loosely correlated
-4.56%
ABCL - DNA
52%
Loosely correlated
-3.50%
NTLA - DNA
52%
Loosely correlated
-0.65%
CRSP - DNA
49%
Loosely correlated
-5.00%
PRME - DNA
49%
Loosely correlated
-5.27%
More